Is Atorvastatin Calcium compatible with breastfeeding? Do we have alternatives for Atorvastatin Calcium?

Atorvastatin Calcium

May 1, 2016 (High Risk)

Statins work by blocking cholesterol synthesis.

At latest update no published data on breastfeeding were found.

A high plasma protein-binding capacity makes it unlikely its passage into milk.
Their low oral bioavailability hinders the passage toward infant’s plasma from ingested mother’s milk, except in preterm infants and immediate neonatal period, in which the infant may have an increased intestinal permeability.

It is unknown whether it is capable of altering the lipid composition of milk, albeit it is known and that the infants need to ingest high amounts of cholesterol because it is essential for a proper development of cell membranes of the nervous system and as a precursor of various hormones and vitamins.

It is prudent to avoid its use, at least while breastfeeding is exclusive. Atorvastatin is possibly the safest statin drug, for its high molecular weight makes it even more difficult the passage into the milk. With Pravastatin a poor secretion into milk has been reported. Simvastatin is the one with lowest oral bioavailability.

Discontinuing the treatment of hypercholesterolemia during lactation with such kind of drugs will not likely alter the long-term outcome of the disease. A low-fat diet should be recommended.

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • Ατορβαστατίνη ασβεστούχος (Greek)
  • Кальций Аторвастатин (Cyrillic)
  • アトルバスタチンカルシウム (Japanese)
  • C66H68CaF2N4O10,3H2O (Molecular formula)

References

  1. Lawrence RA, Lawrence RM. Breastfeeding. A guide for the medical profession. Eighth Edition. Philadelphia: Elsevier; 2016
  2. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011Abstract Full text (link to original source) Full text (in our servers)
  3. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005Abstract Full text (link to original source) Full text (in our servers)
  4. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003Abstract
  5. Whitfield LR, Stern RH, Sedman AJ, Abel R, Gibson DM. Effect of food on the pharmacodynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG-CoA reductase. Eur J Drug Metab Pharmacokinet. 2000Abstract
  6. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996Abstract